Citations

Clear

5 citation(s) found for "Shifren, A".

C104-06 The National Institutes of Health (NIH) Multicenter Safety and Durability of Sirolimus for Lymphangioleiomyomatosis (LAM) (MIDAS) Registry: Real-World Safety and Efficacy of Sirolimus in Lymphangioleiomyomatosis
Darkwah, O A, Gupta, N, McMahan, S, Baker, R, Dilling, D F, Burger, C D, Henske, E, Girod, C E, Ruoss, S J, Veeraraghavan, S, Downey, G P, Koslow, M, Young, L R, Hewlett, J C, Han, M K, Shifren, A, Kotloff, R M, Kreider, M, Strange, C, Barker, A F, Pappas, G P, Morgan, M M, Paine, R, Estrada-Y-Martin, R M, Baqir, M, Parambil, J G, Szczesniak, R, McCormack, F X, Darkwah, Oliveira A G, McMahan, S, Baker, R, Dilling, Daniel F. , Girod, C, Ruoss, Stephen J. , Downey, Gregory P. , Koslow, Matthew , Young, Lisa R. , Hewlett, Justin C. , Han, MeiLan King , Shifren, Adrian , Kotloff, Robert M., Kreider, M., Strange, C, Barker, Amos, Pappas, G.P., Estrada-Y-Martin, Rosa Maria , Baqir, M., Parambil, Joseph G. , Szczesniak, R., McCormack, Francis X.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.2824 Get It

Abstract Rationale Lymphangioleiomyomatosis (LAM) is a rare, progressive, cystic lung disease affecting women. Sirolimus has been shown to stabilize lung function in women with LAM, but real-world data on long-term safety and efficacy are limited. Methods The NIH Multicenter Safety and Durability of Sirolimus for LAM (MIDAS, NCT02432560) observational registry was launched in 2015. All adult (≥18 years) women with LAM (treated or untreated) were eligible to enroll at any of the 20 U.S. sites and followed longitudinally with serial assessments of lung function, health-related quality of life, and treatment related adverse event (TRAEs). Baseline cohort characteristics and TRAEs are summarized using descriptive analyses. Marginal structural models (MSMs) with inverse probability of treatment weighting estimated the causal effect of sirolimus on annualized forced expiratory volume in one-second (FEV1) decline, adjusting for age at LAM diagnosis, prior treatment with sirolimus, menopausal status, race, presence of angiomyolipomas, supplemental oxygen use; time-varying covariates included diffusing capacity for carbon monoxide (DLCO) and serum vascular endothelial growth factor-D (VEGF-D) levels. Results Longitudinal data was available in 350 LAM patients, most of whom (246, 70.3%) had sporadic LAM. The median age at the baseline pulmonary function test (PFT) measurement was 46 years (range: 19 - 74) and the median (IQR) number of serial PFTs obtained per patient was 3 (1 - 5). The average follow-up duration per patient was 2.8 years. Over half of the patients (196, 56%) were treated with sirolimus during the MIDAS observation period for a median (IQR) treatment duration of 4.9 (2.4 - 7.5) years. MSM analysis demonstrated that sirolimus treatment was durably effective and reduced FEV₁ decline by 74.36 mL/year (95% CI: 15.87 - 132.85) compared with no treatment (-85.31 mL/year for the untreated group vs. -10.95 mL/year for the treated group, p = 0.01). Sirolimus was generally well tolerated; treatment interruption ≥3 months was observed in 38 (19.4%) of the 196 sirolimus treated patients. Logistic regression analysis showed that higher levels of FEV1 (odds ratio: OR = 3.12 [1.45 - 7.11], p = 0.005), VEGF-D (OR = 1.0007 [1.0004 - 1.001], p < 0.001), and DLCO (OR = 1.023 [1.0053 - 1.0413, p = 0.01]), were associated with treatment interruption. Conclusions In the MIDAS cohort, sirolimus treatment resulted in durable stabilization of lung function with a favorable safety profile over a 5-year period. These real-world data support sirolimus as a chronic suppressive therapy for LAM, demonstrating durable efficacy in slowing lung disease progression and tolerability with long-term use. This abstract is funded by: National Institutes of Health
Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long?
Cho, Leslie , Kaunitz, Andrew M., Hayes, Sharonne N. , Lau, Emily S. , Pristera, Nicole , Scott, Nandita S. , Shifren, Jan L. , Shufelt, Chrisandra , Stuenkel, Cynthia A. , Hayes, Sharonne N , Lau, Emily S , Scott, Nandita , Shufelt, Chrisandra L , Lindley, Kathryn J , Faubion, Stephanie S.

Mayo Clinic

Circulation | February 13, 2023 | Volume: 147 | Issue: 7 | Pages: 597-610

10.1161/circulationaha.122.061559 | PMID 36780393 Get It

Menopausal hormone therapy (HT) was widely used in the past, but with the publication of seminal primary and secondary prevention trials that reported an excess cardiovascular risk with combined estrogen-progestin, HT use declined significantly. However, over the past 20 years, much has been learned about the relationship between the timing of HT use with respect to age and time since menopause, HT route of administration, and cardiovascular disease risk. Four leading medical societies recommend HT for the treatment of menopausal women with bothersome menopausal symptoms. In this context, this review, led by the American College of Cardiology Cardiolovascular Disease in Women Committee, along with leading gynecologists, women’s health internists, and endocrinologists, aims to provide guidance on HT use, including the selection of patients and HT formulation with a focus on caring for symptomatic women with cardiovascular disease risk.
Knowledge and Needs of Resident Physicians Regarding Osteoporosis: A Nationwide Survey of Residents
Crandall, Carolyn , Rodriguez, Tyler D, Elashoff, David , Kling, Juliana M. , Shifren, Jan L. , Skinner, Lisa J., Bauer, Douglas C. , Crandall, Carolyn J , Bauer, Douglas C , Kling, Juliana M , Chen, Lucia , Rodriguez, Tyler D., Faubion, Stephanie S.

Mayo Clinic

JBMR Plus | June 18, 2021 | Volume: 5 | Issue: 8 | Pages: No page available

10.1002/jbm4.10524 | PMID 34368610 Get It

ABSTRACTLarge‐scale studies have not addressed the knowledge level of US resident physicians regarding osteoporosis management. We gauged the knowledge level of family medicine, internal medicine, and obstetrics and gynecology resident physicians regarding osteoporosis management. In 2019, we sent an anonymous survey via e‐mail to all program directors of Accreditation Council for Graduate Medical Education–accredited residency programs in family medicine, internal medicine, and obstetrics and gynecology for distribution to resident physicians. Knowledge items assessed osteoporosis screening, diagnosis, and treatment. We received responses from 182 family medicine, 275 internal medicine, and 122 obstetrics and gynecology programs. Of 582 resident physician respondents, 31% were family medicine residents, 47% were internal medicine residents, and 21% were obstetrics and gynecology residents. Although 77% of respondents correctly selected the T‐score threshold for the diagnosis of osteoporosis among persons aged 50 years and older (−2.5), only 20% of respondents correctly identified minimal‐trauma hip fracture as being diagnostic of osteoporosis. One‐third of respondents correctly identified which medications were demonstrated in clinical trials to decrease hip fracture risk. Fifteen percent of respondents correctly identified that denosumab and alendronate are associated with osteonecrosis of the jaw; and 40% of respondents correctly identified that decline in bone density is more rapid after discontinuation of denosumab than after discontinuation of bisphosphonates. Less than half of resident physicians knew that bisphosphonate‐associated atypical femoral fractures are duration‐dependent. One‐quarter of respondents felt not at all prepared to manage osteoporosis. In this nationwide survey of resident physicians, knowledge regarding osteoporosis diagnosis and treatment was poor, with a striking lack of knowledge regarding the two most serious adverse effects of osteoporosis pharmacotherapy (osteonecrosis of the jaw and atypical femoral fractures). The undertreatment of osteoporosis is unlikely to improve without increased education of resident physicians. © 2021 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.
The National Academies of Science, Engineering, and Medicine (NASEM) Report on Compounded Bioidentical Hormone Therapy
Pinkerton, JoAnn V. , Kaunitz, Andrew M., Liu, James H., Shifren, Jan L. , Stuenkel, Cynthia A. , Faubion, Stephanie S. , Manson, JoAnn E. , Santoro, Nanette F.

Mayo Clinic

Menopause | October 8, 2020 | Volume: 27 | Issue: 11 | Pages: 1199-1201

10.1097/gme.0000000000001672 | PMID 33110032 Get It

A Phase II Clinical Trial of an Aromatase Inhibitor for Postmenopausal Women with Lymphangioleiomyomatosis
Lu, Calvin, Pappas, George P., Dilling, Daniel F. , Shifren, Adrian , Veeraraghavan, Srihari , Chapman, Jeffrey T., Parambil, Joseph G. , Ruoss, Stephen J. , Young, Lisa R. , Kopras, Elizabeth J. , Roads, Tammy, Krischer, Jeffrey P. , McCormack, Francis X. , McCormack, Francis X , Lu, Calvin, Lee, Hye Seung , Burger, Charles D. , Hammes, Stephen R.

Mayo Clinic

Annals of the American Thoracic Society | June 1, 2017 | Volume: 14 | Issue: 6 | Pages: 919-928

10.1513/annalsats.201610-824oc | PMID 28570161 Get It

Abstract Rationale Lymphangioleiomyomatosis (LAM) is a progressive cystic lung disease that predominantly affects women and can worsen with pregnancy, estrogen treatment, and the menstrual cycle, suggesting an important role for estrogen in disease pathogenesis. Objectives To assess the efficacy and safety of the aromatase inhibitor letrozole in the treatment of LAM. Methods Seventeen postmenopausal women with LAM were enrolled in this phase II trial and randomized to receive letrozole 2.5 mg daily (n = 9) or placebo (n = 8) for a period of 12 months. Five patients in each group were also taking sirolimus at baseline and remained on the drug throughout the treatment period. Lung function, exercise capacity, quality of life, and serum vascular endothelial growth factor D (VEGF-D) were measured at baseline and at 3-month intervals. Results Fifteen patients completed the study. Two patients withdrew. There were no differences in adverse events in the letrozole and placebo groups. The target enrollment of 25 patients per arm was not met, so the efficacy of letrozole could not be assessed as planned. After adjusting for sirolimus use, we found that the rate of change in FEV1 for all subjects was −3 ± 3 ml/mo (P = 0.4), and for serum VEGF-D, the rate of change was −0.024 ± 0.009 pg/ml/mo (P = 0.015), showing a steeper decline in the letrozole group (−0.029 ± 0.013; P = 0.025). All patients who were taking sirolimus had a reduction in VEGF-D levels from baseline to the last visit, compared with only half of the patients who were not taking sirolimus. In a post hoc analysis, eight matched letrozole-treated–placebo-treated pairs were constructed, six of which demonstrated better FEV1 improvement for the letrozole-treated patients. Conclusions Letrozole treatment appears to be safe and well tolerated in postmenopausal patients with LAM, including those taking sirolimus. Enrollment in this trial was compromised by the publication of an effective treatment (sirolimus) in the same month as the study opened, resulting in limited power to detect treatment effects. Post hoc matched pairs exploration studies provide tentative support for additional studies of letrozole in LAM. Considering the reduced rate of lung function decline in postmenopausal patients, future studies will likely require enhanced study designs, such as selective enrollment of those with prognostic biomarkers predictive of decline. Clinical trial registered with www.clinicaltrials.gov (NCT01353209).